The alteration of Hippo/YAP signaling in the development of hypertrophic cardiomyopathy
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Hypertrophic cardiomyopathy (HCM) is a leading cause of heart failure and sudden death in adolescents and young adults. Recently, the role of the Hippo/YAP pathway has been investigated in the pathogenesis of HCM, although the detailed molecular mechanisms largely remain elusive. In this study, we demonstrated an up-regulation of YAP mRNA and protein levels in both HCM patient samples and transverse aortic constriction murine models as well as reduced phosphorylation of YAP at serine 127 accompanied by increased transcription of YAP-mediated genes in hypertrophic heart tissues. The cardiomyocyte-specific transgene of human YAP induced cardiac hypertrophy and increased fetal gene expression in the heart. In primary cultured murine cardiomyocytes, ectopic expression of YAP resulted in increased cellular size, whereas the knockdown of YAP reduced the cell size induced by phenylephrine treatment. Interestingly, both mRNA and protein levels of MST1, the kinase upstream of YAP, were dramatically decreased. Further experiments showed that transcription factor FOXO3 binds to the MST1 promoter and that the PI3 K/Akt/FOXO3 signaling pathway regulates MST1 expression. Our findings define the alteration of the Hippo/YAP pathway in the development of HCM. The exploitation of this pathway may provide a novel therapeutic avenue for this disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, Yap is activated in hearts stressed by pathological pressure overload (144) and in the area bordering a myocardial infarction in mice (25).”
From The Hippo signal transduction network for exercise physiologists (2016) · cites this paper as [144]
In the citing paper
“Yap is expressed at higher levels and dephosphorylated (activated) in samples obtained from pathologically hypertrophied human hearts (144).”
From The Hippo signal transduction network for exercise physiologists (2016) · cites this paper as [144]
Citations
Cites
A Calcineurin-Dependent Transcriptional Pathway for Cardiac Hypertrophy
Molkentin, J. D., Lu, J.-R., Antos, C. L., Markham, B., Richardson, J., Robbins, J., Grant, S. R., & Olson, E. N. (1998) · Cell · doi:10.1016/s0092-8674(00)81573-1 · Cited by 2,566 · cited 1×
“Other downstream mediators of hypertrophy include CaM kinase II [1, 2, 35], calcineurin [25, 27, 32], NFAT [21, 26], and protein kinases C and D [14, 19, 36] as well as members of the MAPK family [18, 20] and the PI3 K-Akt pathway [6, 31].”
BackgroundTEAD mediates YAP-dependent gene induction and growth control
Zhao, B., Ye, X., Yu, J., Li, L., Li, W., Li, S., Yu, J., Lin, J. D., Wang, C.-Y., Chinnaiyan, A. M., et al. (2008) · Genes & Development · doi:10.1101/gad.1664408 · Cited by 2,498
The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal
Zhao, B., Tumaneng, K., & Guan, K.-L. (2011) · Nature Cell Biology · doi:10.1038/ncb2303 · Cited by 1,205 · cited 1×
“The Hippo/MST signaling pathway, first identified in Drosophila, has been delineated as an organ size control pathway [29, 40].”
BackgroundHippo Pathway Inhibits Wnt Signaling to Restrain Cardiomyocyte Proliferation and Heart Size
Heallen, T., Zhang, M., Wang, J., Bonilla-Claudio, M., Klysik, E., Johnson, R. L., & Martin, J. F. (2011) · Science · doi:10.1126/science.1199010 · Cited by 1,092 · cited 1×
“Cardiomyocyte proliferation was shown to be elevated in both the left and right ventricles in the absence of Salvador [16].”
BackgroundZhou, D., Conrad, C., Xia, F., Park, J.-S., Payer, B., Yin, Y., Lauwers, G. Y., Thasler, W., Lee, J. T., Avruch, J., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.09.026 · Cited by 913 · cited 1×
“MST1 and MST2 are key components of the Hippo tumor suppressor pathway, and MST1/2 ablation or YAP overexpression leads to hepatocellular carcinomas [42].”
BackgroundChronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy
Takimoto, E., Champion, H. C., Li, M., Belardi, D., Ren, S., Rodriguez, E. R., Bedja, D., Gabrielson, K. L., Wang, Y., & Kass, D. A. (2005) · Nature Medicine · doi:10.1038/nm1175 · Cited by 903
Hippo signaling in organ size control
Pan, D. (2007) · Genes & Development · doi:10.1101/gad.1536007 · Cited by 647 · cited 1×
“The Hippo/MST signaling pathway, first identified in Drosophila, has been delineated as an organ size control pathway [29, 40].”
BackgroundRegulation of Myocardial Contractility and Cell Size by Distinct PI3K-PTEN Signaling Pathways
Crackower, M. A., Oudit, G. Y., Kozieradzki, I., Sarao, R., Sun, H., Sasaki, T., Hirsch, E., Suzuki, A., Shioi, T., Irie-Sasaki, J., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)00969-8 · Cited by 576
von Gise, A., Lin, Z., Schlegelmilch, K., Honor, L. B., Pan, G. M., Buck, J. N., Ma, Q., Ishiwata, T., Zhou, B., Camargo, F. D., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1116136109 · Cited by 573
Vega, R. B., Harrison, B. C., Meadows, E., Roberts, C. R., Papst, P. J., Olson, E. N., & McKinsey, T. A. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.19.8374-8385.2004 · Cited by 511
CaM kinase II selectively signals to histone deacetylase 4 during cardiomyocyte hypertrophy
Backs, J. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27438 · Cited by 511 · cited 1×
“Other downstream mediators of hypertrophy include CaM kinase II [1, 2, 35], calcineurin [25, 27, 32], NFAT [21, 26], and protein kinases C and D [14, 19, 36] as well as members of the MAPK family [18, 20] and the PI3 K-Akt pathway [6, 31].”
BackgroundAkt/Protein Kinase B Promotes Organ Growth in Transgenic Mice
Shioi, T., McMullen, J. R., Kang, P. M., Douglas, P. S., Obata, T., Franke, T. F., Cantley, L. C., & Izumo, S. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.8.2799-2809.2002 · Cited by 506 · cited 2×
“Accumulating evidence has indicated that the PI3 K/ Akt signaling pathway plays an important role in the development of cardiac hypertrophy [5, 31] and that Akt activation is regulated by YAP [34].”
BackgroundPrevention of Cardiac Hypertrophy in Mice by Calcineurin Inhibition
Sussman, M. A., Lim, H. W., Gude, N., Taigen, T., Olson, E. N., Robbins, J., Colbert, M. C., Gualberto, A., Wieczorek, D. F., & Molkentin, J. D. (1998) · Science · doi:10.1126/science.281.5383.1690 · Cited by 461 · cited 1×
“Other downstream mediators of hypertrophy include CaM kinase II [1, 2, 35], calcineurin [25, 27, 32], NFAT [21, 26], and protein kinases C and D [14, 19, 36] as well as members of the MAPK family [18, 20] and the PI3 K-Akt pathway [6, 31].”
BackgroundAkt induces enhanced myocardial contractility and cell size in vivo in transgenic mice
Condorelli, G., Drusco, A., Stassi, G., Bellacosa, A., Roncarati, R., Iaccarino, G., Russo, M. A., Gu, Y., Dalton, N., Chung, C., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172376399 · Cited by 461 · cited 1×
“Accumulating evidence has indicated that the PI3 K/ Akt signaling pathway plays an important role in the development of cardiac hypertrophy [5, 31] and that Akt activation is regulated by YAP [34].”
BackgroundYAP mediates crosstalk between the Hippo and PI(3)K–TOR pathways by suppressing PTEN via miR-29
Tumaneng, K., Schlegelmilch, K., Russell, R. C., Yimlamai, D., Basnet, H., Mahadevan, N., Fitamant, J., Bardeesy, N., Camargo, F. D., & Guan, K.-L. (2012) · Nature Cell Biology · doi:10.1038/ncb2615 · Cited by 453 · cited 2×
“Accumulating evidence has indicated that the PI3 K/ Akt signaling pathway plays an important role in the development of cardiac hypertrophy [5, 31] and that Akt activation is regulated by YAP [34].”
BackgroundResultPhenotypic Spectrum Caused by Transgenic Overexpression of Activated Akt in the Heart
Matsui, T., Li, L., Wu, J. C., Cook, S. A., Nagoshi, T., Picard, M. H., Liao, R., & Rosenzweig, A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200347200 · Cited by 434 · cited 2×
“The surgical procedure for TAC in mice was performed as previously described [22].”
BackgroundMethodBacks, J., Backs, T., Neef, S., Kreusser, M. M., Lehmann, L. H., Patrick, D. M., Grueter, C. E., Qi, X., Richardson, J. A., Hill, J. A., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813013106 · Cited by 431
Akt Activation Promotes Degradation of Tuberin and FOXO3a via the Proteasome
Plas, D. R., & Thompson, C. B. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m213069200 · Cited by 377 · cited 1×
“3h), we subsequently examined the phosphorylation levels of Akt1 and FOXO3, the latter of which is one of the major targets of Akt signaling [30].”
BackgroundWettschureck, N., Rütten, H., Zywietz, A., Gehring, D., Wilkie, T. M., Chen, J., Chien, K. R., & Offermanns, S. (2001) · Nature Medicine · doi:10.1038/nm1101-1236 · Cited by 373
Decoding calcium signals involved in cardiac growth and function
Frey, N., McKinsey, T. A., & Olson, E. N. (2000) · Nature Medicine · doi:10.1038/81321 · Cited by 344 · cited 1×
“Hypertrophic stimuli trigger autocrine/paracrine signaling pathways that stimulate Gaq/Ga11 protein-coupled receptors (GPCRs) including the angiotensin, endothelin and a1-adrenergic receptors [11, 13, 28].”
BackgroundMende, U., Kagen, A., Cohen, A., Aramburu, J., Schoen, F. J., & Neer, E. J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.23.13893 · Cited by 258 · cited 1×
“Other downstream mediators of hypertrophy include CaM kinase II [1, 2, 35], calcineurin [25, 27, 32], NFAT [21, 26], and protein kinases C and D [14, 19, 36] as well as members of the MAPK family [18, 20] and the PI3 K-Akt pathway [6, 31].”
BackgroundCarniel, E., Taylor, M. R. G., Sinagra, G., Di Lenarda, A., Ku, L., Fain, P. R., Boucek, M. M., Cavanaugh, J., Miocic, S., Slavov, D., et al. (2005) · Circulation · doi:10.1161/circulationaha.104.507699 · Cited by 247
Role for G 12 /G 13 in Agonist-Induced Vascular Smooth Muscle Cell Contraction
Gohla, A., Schultz, G., & Offermanns, S. (2000) · Circulation Research · doi:10.1161/01.res.87.3.221 · Cited by 210
Fananapazir, L., Dalakas, M. C., Cyran, F., Cohn, G., & Epstein, N. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.9.3993 · Cited by 196 · cited 1×
“expression pattern for Myh6 and Myh7, markers of HCM [3, 9] (Fig.”
BackgroundChaanine, A. H., Jeong, D., Liang, L., Chemaly, E. R., Fish, K., Gordon, R. E., & Hajjar, R. J. (2012) · Cell Death & Disease · doi:10.1038/cddis.2012.5 · Cited by 167
Regulation of Cardiac Stress Signaling by Protein Kinase D1
Harrison, B. C., Kim, M.-S., van Rooij, E., Plato, C. F., Papst, P. J., Vega, R. B., McAnally, J. A., Richardson, J. A., Bassel-Duby, R., Olson, E. N., et al. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.10.3875-3888.2006 · Cited by 154
CaMKII Negatively Regulates Calcineurin–NFAT Signaling in Cardiac Myocytes
MacDonnell, S. M., Weisser-Thomas, J., Kubo, H., Hanscome, M., Liu, Q., Jaleel, N., Berretta, R. M., Chen, X., Brown, J. H., Sabri, A. K., et al. (2009) · Circulation Research · doi:10.1161/circresaha.109.194035 · Cited by 150
1-Adrenergic receptors prevent a maladaptive cardiac response to pressure overload
O'Connell, T. D. (2006) · Journal of Clinical Investigation · doi:10.1172/jci22811 · Cited by 141
Extracellular signal‐regulated kinase 1/2 (ERK1/2) signaling in cardiac hypertrophy
Kehat, I., & Molkentin, J. D. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05088.x · Cited by 136 · cited 1×
“Other downstream mediators of hypertrophy include CaM kinase II [1, 2, 35], calcineurin [25, 27, 32], NFAT [21, 26], and protein kinases C and D [14, 19, 36] as well as members of the MAPK family [18, 20] and the PI3 K-Akt pathway [6, 31].”
BackgroundLats2 Is a Negative Regulator of Myocyte Size in the Heart
Matsui, Y., Nakano, N., Shao, D., Gao, S., Luo, W., Hong, C., Zhai, P., Holle, E., Yu, X., Yabuta, N., et al. (2008) · Circulation Research · doi:10.1161/circresaha.108.180042 · Cited by 131 · cited 2×
“In accordance with the finding that MST1 and Lats2 reduce cardiomyocyte size [23], we found that the overexpression of YAP increased cell size and the expression of fetal genes in primary mouse cardiomyocytes.”
BackgroundResultSelf-citationCardiac hypertrophy: Targeting Raf/MEK/ERK1/2-signaling
Lorenz, K., Schmitt, J. P., Vidal, M., & Lohse, M. J. (2009) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2009.08.002 · Cited by 128 · cited 1×
“Other downstream mediators of hypertrophy include CaM kinase II [1, 2, 35], calcineurin [25, 27, 32], NFAT [21, 26], and protein kinases C and D [14, 19, 36] as well as members of the MAPK family [18, 20] and the PI3 K-Akt pathway [6, 31].”
BackgroundDel Re, D. P., Matsuda, T., Zhai, P., Gao, S., Clark, G. J., Van Der Weyden, L., & Sadoshima, J. (2010) · Journal of Clinical Investigation · doi:10.1172/jci43569 · Cited by 126 · cited 1×
“For example, the suppression of the Rassf1A/MST1 pathway in cardiomyocytes was shown to inhibit apoptosis, whereas the inhibition of Rassf1A/MST1 in fibroblasts stimulates the secretion of TNF-a, which in turn enhances cardiac hypertrophy through a paracrine mechanism [7].”
BackgroundFlores-Munoz, M., Work, L. M., Douglas, K., Denby, L., Dominiczak, A. F., Graham, D., & Nicklin, S. A. (2012) · Hypertension · doi:10.1161/hypertensionaha.111.177485 · Cited by 105
Parati, G., Omboni, S., Staessen, J., Thijs, L., Fagard, R., Ulian, L., & Mancia, G. (1998) · Journal of Hypertension · doi:10.1097/00004872-199816010-00005 · Cited by 81
Protein kinase Cα as a heart failure therapeutic target
Liu, Q., & Molkentin, J. D. (2010) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2010.10.004 · Cited by 76
The importance of left ventricular hypertrophy in human hypertension.
Kahan, T. (1998) · PubMed · Cited by 71
On the mechanism of compensatory hyperfunction and insufficiency of the heart.
Fz, M. (1961) · PubMed · Cited by 63
Cardiac Hypertrophy and Heart Failure Development Through Gq and CaM Kinase II Signaling
Mishra, S., Ling, H., Grimm, M. F., Zhang, T., Bers, D. M., & Brown, J. H. (2010) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e3181e1d263 · Cited by 62 · cited 1×
“Other downstream mediators of hypertrophy include CaM kinase II [1, 2, 35], calcineurin [25, 27, 32], NFAT [21, 26], and protein kinases C and D [14, 19, 36] as well as members of the MAPK family [18, 20] and the PI3 K-Akt pathway [6, 31].”
BackgroundTherapeutic options in minimizing left ventricular hypertrophy
Devereux, R. B. (2000) · American Heart Journal · doi:10.1067/mhj.2000.102902 · Cited by 46 · cited 1×
“converting enzyme inhibitors [10, 17] and angiotensin II type 1 receptor blockers [8], target outside-in signaling pathways in cardiac cells.”
BackgroundGeorgescu, S. P., Aronovitz, M. J., Iovanna, J., Patten, R. D., Kyriakis, J. M., & Goruppi, S. (2011) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00211.2011 · Cited by 42 · cited 1×
“In addition to Akt activation, CTGF expression has also been shown to be elevated in TAC mice [12], which is in agreement with our results (Fig.”
ResultValencia, T. G., Roberts, L. D., Zeng, H., & Grant, S. R. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3239 · Cited by 15 · cited 1×
“Other downstream mediators of hypertrophy include CaM kinase II [1, 2, 35], calcineurin [25, 27, 32], NFAT [21, 26], and protein kinases C and D [14, 19, 36] as well as members of the MAPK family [18, 20] and the PI3 K-Akt pathway [6, 31].”
Background
Research works printed but not linked: 2
- Heallen T, Zhang M, Wang J, Bonilla-Claudio M, Klysik E, Johnson RL, Martin JF (2011) Hippo pathway inhibits Wnt signaling to restrain cardiomyocyte proliferation and heart size. Science 332:458–461. doi: 10.1126/science.1199010 · DOI · Paper page
- von Gise A, Lin Z, Schlegelmilch K, Honor LB, Pan GM, Buck JN, Ma Q, Ishiwata T, Zhou B, Camargo FD, Pu WT (2011) YAP1, the nuclear target of Hippo signaling, stimulates heart growth through cardiomyocyte proliferation but not hypertrophy. Proc Natl Acad Sci USA 109:2394–2399. doi: 10.1073/pnas.1116136109 · DOI · Paper page
Cited by
Mechanisms of physiological and pathological cardiac hypertrophy
Nakamura, M., & Sadoshima, J. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0007-y · Cited by 1,658
The Hippo signalling pathway and its implications in human health and diseases
Fu, M., Hu, Y., Lan, T., Guan, K.-L., Luo, T., & Luo, M. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01191-9 · Cited by 742
“298 However, the condition seems to be different in ARCV 299 and DCM, 300 in which the Hippo pathway was activated, leading to YAP inactivation.”
BackgroundThe Hippo pathway in the heart: pivotal roles in development, disease, and regeneration
Wang, J., Liu, S., Heallen, T., & Martin, J. F. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0063-3 · Cited by 380
The Hippo Pathway in Heart Development, Regeneration, and Diseases
Zhou, Q., Li, L., Zhao, B., & Guan, K.-L. (2015) · Circulation Research · doi:10.1161/circresaha.116.303311 · Cited by 219
Ikeda, S., Mizushima, W., Sciarretta, S., Abdellatif, M., Zhai, P., Mukai, R., Fefelova, N., Oka, S., Nakamura, M., Re, D. P. D., et al. (2019) · Circulation Research · doi:10.1161/circresaha.118.314048 · Cited by 129
Metadata
- Authors
- Wang, P., Mao, B., Luo, W., Wei, B., Jiang, W., Liu, D., Song, L., Ji, G., Yang, Z., Lai, Y.-Q., & Yuan, Z.
- Affiliations
- Capital Medical University (CN)
- Chinese Academy of Sciences (CN)
- Model Animal Research Center (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Corresponding author
- Yang, Zhongzhou
- Yuan, Zengqiang
- ORCID
- Venue
- Basic Research in Cardiology
- Published
- 2014-08-29
- Volume
- 109
- Issue
- 5
- Pages
- 435-435
- ISSN
- 0003-9217 (ISSN-L)
- 0300-8428
- 1435-1803
- OpenAlex
- W1969614725
- Cited by
- 83
- References
- 41
- Citations by year
- 2026: 9 · 2025: 6 · 2024: 13 · 2023: 6 · 2022: 11 · 2021: 8 · 2020: 7 · 2019: 4 · 2018: 4 · 2017: 3 · 2016: 7 · 2015: 4 · 2014: 1
- FWCI
- 2.49
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Basic Research in Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Family Process Institute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Hippo pathway signaling and YAP/TAZ
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiomyopathy and Myosin Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Congenital heart defects research
- Keywords
- hypertrophic cardiomyopathy, Hippo/YAP signaling, YAP phosphorylation, MST1, FOXO3, PI3K/Akt signaling, cardiac hypertrophy, transverse aortic constriction, cardiomyocyte size, fetal gene expression, therapeutic target
- MeSH terms
- Hippo Signaling Pathway, YAP-Signaling Proteins, Adult, Aged, Animals, Cardiomyopathy, Hypertrophic, Female, Fluorescent Antibody Technique, Humans, Male, Mice, Inbred C57BL, Middle Aged, Phosphoproteins, Signal Transduction, Protein Serine-Threonine Kinases, Cell Cycle Proteins, Chromatin Immunoprecipitation, Adaptor Proteins, Signal Transducing, Mice, Real-Time Polymerase Chain Reaction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.